From: Broad spectrum vasopressors: a new approach to the initial management of septic shock?
Vasopressin [14] | Angiotensin II [6] | |||||
---|---|---|---|---|---|---|
Responder 45% (n = 426) | Non-responder 55% (n = 512) | P value | Responder 69.9% (n = 114) | Non-responder 30.1% (n = 49) | P value | |
In-patient mortality (%) | 56.6% | 71.7% | < 0.001 | 35% | 71% | < 0.0001 |
Catecholamine dose (mcg/kg/min) | 0.35 ± 0.25 | 0.33 ± 0.27 | 0.18 | 0.32 ± 0.32 | 0.53 ± 0.39 | 0.0002 |
MAP (mmHg) | 69 ± 12 | 65 ± 12 | < 0.001 | 67.1 ± 5.21 | 64.8 ± 5.02 | 0.0087 |
Steroids (%) | 58.9 | 62.5 | 0.26 | 55.3 | 57.1 | 0.8647 |
Lactate (mmol/L) | 4.0 ± 3.6 | 5.4 ± 4.8 | < 0.001 | 3.43 ± 2.43 | 5.80 ± 6.01 | 0.013 |
SOFA score | 13 ± 4 | 12 ± 3 | 0.49 | 11.65 ± 2.78 | 12.06 ± 2.99 | 0.4313 |
Age, years | 62 ± 14 | 61 ± 15 | 0.17 | 61.7 ± 15.32 | 63.1 ± 16.33 | 0.4278 |